An employer did not breach its duty to make reasonable adjustments for an employee with a stammer when it held internal promotion interviews via video conference. The employee’s stammer made him curtail his answers in the interview, which negatively affected his assessment. However, he had not told his employer that his stammer might have this effect and, on the facts of this case, the employer was reasonable in not realizing it.
The government has announced the annual increases to tribunal compensation awards and statutory redundancy payments from 6 April 2024.
Following calls by the European Parliament for potentially far-reaching changes, the European Commission has now kicked off the EU legislative process to revise the European Works Council Directive. This alert provides an update on the Commission’s proposals, and we will issue further alerts as the legislative process continues.
A number of employment law changes will, or are expected to, come into force in April in the UK that employers should make note of. We have summarized them here for reference.
On 13 February 2024, the FCA issued a Final Notice to Floris Jakobus Huisamen, the former director and compliance officer of London Capital & Finance plc (LCF), fining him GBP 31,800 and banning him from working in financial services in relation to misconduct connected to financial promotions issued by LCF. This Final Notice follows the FCA’s previous censure of LCF in October 2023 for connected behaviour. In this alert we draw out the key takeaways that compliance officers should bear in mind from the FCA’s enforcement action.
On 31 January 2024, the Italian Medicines Agency (AIFA) published the Guidelines on applications for marketing authorizations submitted through the national procedure. The purpose of the Guidelines is to provide detailed information about (i) the correct submission of applications for marketing authorization and the relevant administrative and technical documentation, (ii) the steps and timeframes for the AIFA’s assessment of such applications, including any requests for clarification and/or further documentation, and (iii) the publication of the results of the preliminary assessment, the procedures for issuing the final resolutions as well as for their notification and publication in the Official Gazette.
On 23 January 2024, the European Medicines Agency published an updated version of the user guide for micro, small and medium-sized enterprises in the pharmaceutical sector. The revised guide offers comprehensive information on the EU legislative framework for medicines, outlining requirements for the development and authorization of medicines for human and veterinary use.
On 6 February 2024, the AIFA published the updated list of self-certified healthcare facilities allowed to perform phase I clinical trials pursuant to Determination No. 809/2015, which defines the minimum requirements for such centers.
On 5 January 2024, the Italian Medicines Agency (AIFA)’s Resolution No. DG/526/2023 providing the list of medicines that must not be withdrawn from distribution and sale within the national territory, which, therefore, can’t be exported, was published in the Official Gazette.
With Decree of 29 December 2023, published on 9 February 2024, the Ministry of Health identified the criteria and procedures for the payment of the annual fees for the monitoring and management of the Fund for the Governance of Medical Devices referred to in Article 28 of Legislative Decree No. 137/2022.